Advertisement
Advertisement
Zelira Therapeutics Reports Increased Loss Amidst Clinical Progress and Expansion Plans
PremiumCompany AnnouncementsZelira Therapeutics Reports Increased Loss Amidst Clinical Progress and Expansion Plans
3M ago
Zelira Therapeutics Advances Diabetic Neuropathy Study and Strengthens Financial Position
Premium
Company Announcements
Zelira Therapeutics Advances Diabetic Neuropathy Study and Strengthens Financial Position
4M ago
Zelira Therapeutics Secures $650,000 R&D Loan Facility to Advance Clinical Trials
Premium
Company Announcements
Zelira Therapeutics Secures $650,000 R&D Loan Facility to Advance Clinical Trials
4M ago
Zelira Therapeutics Expands Market Presence with New Securities Quotation
PremiumCompany AnnouncementsZelira Therapeutics Expands Market Presence with New Securities Quotation
8M ago
Zelira Therapeutics Launches Share Offer to Raise Capital
Premium
Company Announcements
Zelira Therapeutics Launches Share Offer to Raise Capital
8M ago
Zelira Therapeutics Announces Proposed Issue of 550,000 Securities
Premium
Company Announcements
Zelira Therapeutics Announces Proposed Issue of 550,000 Securities
8M ago
Zelira Therapeutics Secures Fourth Funding Tranche to Advance FDA Trials
PremiumCompany AnnouncementsZelira Therapeutics Secures Fourth Funding Tranche to Advance FDA Trials
10M ago
Zelira Therapeutics Announces Change in Director’s Interest
Premium
Company Announcements
Zelira Therapeutics Announces Change in Director’s Interest
10M ago
Zelira Therapeutics Issues Convertible Notes
Premium
Company Announcements
Zelira Therapeutics Issues Convertible Notes
11M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100